Strimvelis (autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence) / Kyowa Kirin 
Welcome,         Profile    Billing    Logout  
 0 Diseases   3 Trials   3 Trials   176 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Strimvelis (autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence) / Kyowa Kirin
2017-001731-39: Retroviral insertion site methodology study Studio metodologico sui siti di inserzione retrovirale

Ongoing
4
15
Europe
Strimvelis, [NA], Powder for solution for infusion, Strimvelis
Orchard Therapeutics (Europe) Ltd, ORCHARD THERAPEUTICS LTD
Adenosine deaminase (ADA) deficiency severe combined immunodeficiency Adenosina deaminasi grave combinata a immunodeficienza, ADA-SCID ADA-SCID, Diseases [C] - Immune System Diseases [C20]
 
 
NCT04959890: Methodology Study of Retroviral Insertion Site Analysis in Strimvelis Gene Therapy

Active, not recruiting
N/A
15
Europe
Strimvelis
Fondazione Telethon
Severe Combined Immunodeficiency Due to ADA Deficiency
03/24
03/24
NCT03478670: Strimvelis Registry Study to Follow-up Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID)

Enrolling by invitation
N/A
50
Europe
Strimvelis
Fondazione Telethon
Immunologic Deficiency Syndromes
05/37
05/37

Download Options